NCT00725478View on ClinicalTrials.gov

SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease

CompletedOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Parkinson's Disease
Interventions
DRUG

Piribedil

Sponsors
All Listed Sponsors
lead

Desitin Arzneimittel GmbH

INDUSTRY

NCT00725478 - SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease | Biotech Hunter | Biotech Hunter